Strong performance in complex generics, ongoing biosimilar uptake and successful new product launches all provided a boost to Amneal Pharmaceuticals, Inc.’s off-patent unit during Q3, the company has reported. The generics segment ultimately grew by 12% annually, bringing in $390.8m, compared to $350.2m during Q3 2022.
Key takeaways:
-
Amneal’s generics unit brought in over $390m during the third quarter of 2023, representing 13% annual growth, as a result of the firm’s continued shift toward complex generic products, biosimilar uptake and successful launches of new products
Ahead of its earnings report, Amneal had raised its 2023 guidance for a second time this year, anticipating annual net...







